Table 2 Characteristics of patients and samples in the p53 substudy.
Arm (A+AC) Anthracycline Control Arms N = 167 | Arm (AT+A-T) Docetaxel Arms N = 353 | Total N = 520 | Pvalue (Chi-square Test)* | ||
|---|---|---|---|---|---|
Age (years) | Median | 48 | 49 | 49 | 0.193 |
Range | 27-66 | 26-70 | 26-70 | ||
< 35 | 12 (7.2%) | 22 (6.2%) | 34 (6.5%) | ||
35-49 | 88 (52.7%) | 167 (47.3%) | 255 (49.0%) | ||
50-65 | 65 (38.9%) | 148 (41.9%) | 213 (41.0%) | ||
> 65 | 2 (1.2%) | 16 (4.5%) | 18 (3.5%) | ||
Menopausal status | Premenopausal | 104 (62.3%) | 212 (60.0%) | 316 (60.7%) | 0.628 |
Postmenopausal | 63 (37.7%) | 141 (39.9%) | 204 (39.3%) | ||
Body Mass Index (BMI) | Nonobese (BMI < 30) | 135 (80.8%) | 283 (80.2%) | 418 (80.4%) | 0.858 |
Obese (BMI > = 30) | 32 (19.2%) | 70 (19.8%) | 102 (19.6%) | ||
Histopathology | Infiltrating ductal ca. | 139 (83.2) | 285 (80.7%) | 424 (81.5%) | 0.441 |
Infiltrating lobular ca. | 13 (7.8%) | 40 (11.3%) | 53 (10.2%) | ||
Other | 15 (8.9%) | 28 (7.9%) | 43 (8.3%) | ||
Tumor size (pT) | T1 | 55 (32.9%) | 96 (27.2%) | 151 (29.0%) | 0.397 |
T2 | 102 (61.1%) | 224 (63.4%) | 326 (62.7%) | ||
T3 | 9 (5.4%) | 29 (8.2%) | 38 (7.3%) | ||
Missing | 1 (0.6%) | 4 (1.1%) | 5 (0.9%) | ||
Number of positive lymph nodes | 1-3 | 83 (49.7%) | 189 (53.5%) | 272 (52.3%) | 0.610 |
≥ 4 | 84 (50.3%) | 164 (46.4%) | 248 (47.7%) | ||
Histopathologic grade | G1 | 9 (5.4%) | 27 (7.6%) | 36 (6.9%) | 0.204 |
G2 | 77 (46.1%) | 153 (43.3%) | 230 (44.2%) | ||
G3 | 76 (45.5%) | 170 (48.1%) | 246 (47.3%) | ||
Missing | 5 (3.0%) | 3 (0.8%) | 8 (1.5%) | ||
ER/PgR status | ER+/PgR+ | 106 (63.5%) | 265 (75.1%) | 371 (71.3%) | 0.046 |
ER+/PgR- | 12 (7.2%) | 20 (5.7%) | 32 (6.1%) | ||
ER-/PgR- | 40 (23.9%) | 58 (16.4%) | 98 (18.8%) | ||
Other/missing | 9 (5.4%) | 10 (2.8%) | 19 (3.6%) | ||
HER2 status | HER2- | 126 (75.4%) | 288 (81.6%) | 414 (79.6%) | 0.113 |
HER2+ | 33 (19.7%) | 58 (16.4%) | 91 (17.5%) | ||
Missing | 8 (4.8%) | 7 (1.9%) | 15 (2.9%) | ||
IHC subtypes** | Luminal A | 28 (16.8%) | 56 (15.9%) | 84 (16.1%) | 0.052 |
Luminal B | 88 (52.7%) | 227 (64.3%) | 315 (60.6%) | ||
HER2 | 15 (8.9%) | 17 (4.8%) | 32 (6.2%) | ||
Triple-negative | 25 (14.9%) | 41 (11.6%) | 66 (12.7%) | ||
Missing | 11 (6.6%) | 12 (3.4%) | 23 (4.4%) | ||
p53 status | Wild-type | 134 (80.2%) | 301 (85.3%) | 435 (83.6%) | 0.147 |
Mutated | 33 (19.8%) | 52 (14.7%) | 85 (16.3%) | ||
Hormonotherapy use | Received tamoxifen | 118 (70.6%) | 274 (77.6%) | 392 (75.4%) | 0.085 |
Did not receive tamoxifen | 49 (29.4%) | 79 (22.4%) | 128 (24.6%) |